{
    "nct_id": "NCT03650491",
    "official_title": "A Phase I Study of FOR46 Administered Every 21 Days in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)",
    "inclusion_criteria": "* Male or female ≥ 18 years of age\n* Measurable MM that is relapsed or refractory to established therapies with known clinical benefit in RRMM or intolerant of those established MM therapies. Prior lines of therapy must include a proteasome inhibitor (PI), an immunomodulatory imide drug (IMiD) and a CD38-directed therapy in any order of combination.\n* ECOG performance status of 0 or 1\n* Adequate hematologic, renal and hepatic function\n* Females of child-bearing potential must have a negative serum pregnancy test and use a medically acceptable form of contraception\n* Male patients with with female partners of childbearing potential must agree to use 2 effective methods of contraception\n* Patients must provide signed informed consent\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Persistent clinically significant toxicities from previous anticancer therapy\n* NCI CTCAE Grade ≥ 2 peripheral neuropathy from any etiology or has a genetic disorder that is associated with peripheral neuropathy even without current neuropathic manifestations\n* Has received treatment with a stem cell transplant within 12 weeks before administration of patient's first dose of FOR46\n* Has had radiation or systemic anticancer therapy within 14 days before first dose of FOR46\n* Has received treatment with an investigational drug within 28 days before first dose of FOR46\n* Has had a major surgical procedure within 28 days before administration of the patient's first FOR46 dose\n* Is breastfeeding\n* Clinically significant cardiovascular disease\n* Uncontrolled, clinically significant pulmonary disease\n* Uncontrolled intercurrent illness\n* Has known positive status for HIV or either active/chronic hepatitis B/C\n* Requires anticoagulation with warfarin or direct thrombin inhibitor; a washout of 7 days before the administration of a patient's first FOR46 dose is required for patients removed from these treatments\n* Requires medications that are strong inhibitors or strong inducers of CYP3A4\n* Has a history of episodic atrial fibrillation or flutter; patients with chronic atrial fibrillation are not excluded.\n* Prior treatment with an ADC containing Monomethyl auristatin E (MMAE) or Monomethyl auristatin F (MMAF).",
    "miscellaneous_criteria": ""
}